Morgan Stanley Exicure, Inc. Transaction History

Morgan Stanley

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 17, 2024	SELL	$0.3 - $0.64 $4 - $8	-14 Reduced 0.45%	3,072 $0
Q2 2024 Aug 14, 2024	SELL	$0.3 - $0.64 $4 - $8	-14 Reduced 0.45%	3,072 $0
Q1 2024 Oct 17, 2024	BUY	$0.53 - $0.84 $7 - $11	14 Added 0.46%	3,086 $1,000
Q1 2024 Aug 16, 2024	SELL	$0.53 - $0.84 $98 - $155	-185 Reduced 5.66%	3,086 $1,000
Q1 2024 May 15, 2024	SELL	$0.53 - $0.84 $98 - $155	-185 Reduced 5.66%	3,086 $1,000
Q4 2023 Aug 16, 2024	BUY	$0.37 - $0.75 $73 - $149	199 Added 6.48%	3,271 $1,000
Q4 2023 Feb 13, 2024	SELL	$0.37 - $0.75 $34 - $69	-92 Reduced 2.74%	3,271 $1,000
Q3 2023 Nov 15, 2023	SELL	$0.71 - $1.36 $20 - $39	-29 Reduced 0.85%	3,363 $2,000
Q1 2023 May 15, 2023	BUY	$0.78 - $1.58 $677 - $1,371	868 Added 34.39%	3,392 $2,000
Q4 2022 Feb 14, 2023	SELL	$0.71 - $9.3 $304 - $3,989	-429 Reduced 14.53%	2,524 $2,000
Q3 2022 Nov 14, 2022	SELL	$1.53 - $8.5 $2,129 - $11,832	-1,392 Reduced 32.04%	2,953 $5,000
Q2 2022 Aug 15, 2022	BUY	$2.16 - $6.36 $9,385 - $27,634	4,345 New	4,345 $9,000

287K

Ticker XCUR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,962,580
Market Cap $55.5M
Description
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.